Latest Heartware Intl Inc (HWIFF) Headlines
HeartWare Receives FDA Approval To Enroll Supplemental Patient Cohort In Destination Therapy Trial
PR Newswire - Tue Aug 27, 8:10AM CDT
HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that the U.S. Food and Drug Administration (FDA) has approved an IDE (Investigational Device Exemption) Supplement that allows HeartWare to commence enrollment in an additional patient cohort for ENDURANCE, the Company's pivotal, Destination Therapy clinical study.
Investment Initiatives, Financial Results, Investor Conferences, Dividends, and FDA Approvals - Research Report on CareFusion, Teleflex, Cooper, HeartWare, and Thoratec
PR Newswire - Thu Aug 15, 7:00AM CDT
Editor Note: For more information about this release, please scroll to bottom.
HeartWare Presentation At The Canaccord Genuity 2013 Annual Growth Conference To Be Webcast
PR Newswire - Fri Aug 09, 3:00PM CDT
HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Canaccord Genuity 2013 Annual Growth Conference at 3:00 p.m. EDT on Wednesday, August 14, 2013. The conference is being held August 14-15 at the The InterContinental Boston.
HeartWare International Reports $50.8 Million In Second Quarter 2013 Revenue; 75% Increase From Second Quarter Of 2012
PR Newswire - Thu Aug 08, 6:00AM CDT
HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced revenue of $50.8 million for the second quarter ended June 30, 2013, a 75% increase compared to $29.1 million in revenue for the same period of 2012.
HeartWare Schedules Second Quarter Conference Call And Webcast
PR Newswire - Fri Jul 19, 5:00AM CDT
HeartWare International, Inc. (NASDAQ:HTWR, ASX:HIN) has scheduled a conference call to discuss its financial results for the three months ended June 30, 2013, at 8:00 a.m. U.S. Eastern Daylight Time on Thursday, August 8, 2013. The Company plans to release the financial results prior to the conference call.
Leadership Changes, New Studies, Acquisitions, New Care Facilities, and Business Transformations - Research Report on Cigna, HeartWare, Acadia, Magellan, and Haemonetics
PR Newswire - Tue Jun 25, 7:00AM CDT
Today, Wall Street Reports announced new research reports highlighting CIGNA Corporation (NYSE: CI), HeartWare International Inc. (NASDAQ: HTWR), Acadia Healthcare Company Inc. (NASDAQ: ACHC), Magellan Health Services Inc. (NASDAQ: MGLN), and Haemonetics Corporation (NYSE: HAE). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
HeartWare Receives Conditional Approval From FDA to Enroll Supplemental Patient Cohort in Destination Therapy Trial
PR Newswire - Mon Jun 17, 7:50AM CDT
HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that the U.S. Food and Drug Administration (FDA) has granted conditional approval to an IDE (Investigational Device Exemption) Supplement that allows HeartWare to commence enrollment in an additional patient cohort for ENDURANCE, the Company's pivotal, Destination Therapy clinical study.
HeartWare Presentation at the Wells Fargo Securities 2013 Healthcare Conference to be Webcast
PR Newswire - Thu Jun 13, 8:00AM CDT
HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Wells Fargo Securities Research and Economics 2013 Healthcare Conference at 9:25 a.m. EDT on Tuesday, June 18, 2013. The conference is being held June 18-19 at the The InterContinental Boston.
HeartWare International Announces Intention To Delist From Australian Securities Exchange (ASX)
PR Newswire - Wed Jun 12, 7:00AM CDT
HeartWare International, Inc. (NASDAQ:HTWR - ASX:HIN), today announced that it has requested and received approval from ASX Limited for its removal from the official list of ASX. Trading in HeartWare's CHESS Depositary Interests (CDIs) will be suspended on ASX at the close of market on September 10, 2013.
HeartWare Presentation At The Goldman Sachs 34th Annual Global Healthcare Conference To Be Webcast
PR Newswire - Tue Jun 04, 11:20AM CDT
HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Goldman Sachs 34th Annual Global Healthcare Conference at 8:00 a.m. PDT (11:00 am EDT) on Wednesday, June 12, 2013. The conference is being held June 11-13 at the Terranea Resort in Rancho Palos Verdes, CA.
HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be Webcast
PR Newswire - Thu May 16, 3:00PM CDT
HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the 2013 UBS Global Healthcare Conference at 11:00 a.m. EDT on Monday, May 20, 2013. The conference is being held May 20-22, 2013 at the Sheraton New York Hotel.
HeartWare Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference to be Webcast
PR Newswire - Fri May 10, 12:59PM CDT
HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Bank of America Merrill Lynch 2013 Health Care Conference at 8:00 a.m. PDT (11:00 am EDT) on Thursday, May 16, 2013. The conference is being held May 14-16, 2013 at the Encore at Wynn in Las Vegas.
HeartWare International Reports $49.2 Million In First Quarter 2013 Revenue; 87% Increase From First Quarter Of 2012
PR Newswire - Mon Apr 29, 3:10PM CDT
HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced revenue of $49.2 million for the first quarter ended March 31, 2013, an 87% increase compared to $26.4 million in revenue for the same period of 2012.
HeartWare Schedules First Quarter Conference Call And Webcast
PR Newswire - Mon Apr 15, 5:00AM CDT
HeartWare International, Inc. (NASDAQ: HTWR, ASX:HIN) has scheduled a conference call to discuss its financial results for the three months ended March 31, 2013, at 5:00 p.m. U.S. Eastern Daylight Time on Monday, April 29, 2013. The Company plans to release the financial results prior to the conference call.
HeartWare International, Inc. Announces Closing of Public Offering of Common Stock
PR Newswire - Mon Mar 18, 11:21AM CDT
HeartWare International, Inc. (Nasdaq: HTWR, ASX: HIN) ("HeartWare") announced today the completion of a public offering of 1,725,000 shares of common stock, at a price per share of $86.45 pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission ("SEC") on December 9, 2010. This amount includes 225,000 additional shares of common stock sold pursuant to the underwriters' exercise in full of their option to purchase additional shares of common stock to cover over-allotments.
HeartWare International, Inc. Announces Pricing of Public Offering of Common Stock
PR Newswire - Tue Mar 12, 7:41PM CDT
HeartWare International, Inc. (Nasdaq: HTWR, ASX: HIN) ("HeartWare") announced today the pricing of a public offering of 1,500,000 shares of common stock at a price per share of $86.45 pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission ("SEC"). HeartWare also granted the underwriters an option to purchase up to an additional 225,000 shares to cover over-allotments, if any.
HeartWare International, Inc. Announces Public Offering of Common Stock
PR Newswire - Mon Mar 11, 3:00PM CDT
HeartWare International, Inc. (Nasdaq: HTWR, ASX: HIN) ("HeartWare") announced today its intention to offer, subject to market and other conditions, 1,500,000 shares of common stock pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission ("SEC"). HeartWare also intends to grant the underwriters an option to purchase up to an additional 225,000 shares to cover over-allotments, if any.
Leveraging Results to Drive New Innovation - Research Report on Medtronic, Inc., Edwards Lifesciences, Cyberonics, Inc., HeartWare International and Luxottica Group SpA
PR Newswire - Thu Mar 07, 7:00AM CST
Today, Investors Alliance announced new research reports highlighting Medtronic, Inc. (NYSE:MDT), Edwards Lifesciences Corp (NYSE:EW), Cyberonics, Inc. (NASDAQ:CYBX), HeartWare International Inc (NASDAQ:HTWR) and Luxottica Group SpA (NYSE:LUX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
HeartWare Presentation at the Barclays Capital 2013 Global Healthcare Conference To Be Webcast
PR Newswire - Wed Mar 06, 8:00AM CST
HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Barclays Capital 2013 Global Healthcare Conference at 11:15 a.m. EDT on Tuesday, March 12, 2013. The conference is being held March 12-14, 2013 at the Loews Miami Hotel, Florida.
HeartWare Presentation At Raymond James 34th Annual Institutional Investors Conference To Be Webcast
PR Newswire - Thu Feb 28, 9:47AM CST
HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Raymond James 34th Annual Institutional Investors Conference at 1:05 p.m. Eastern Standard Time on Tuesday, March 5, 2013. The conference is being held March 3-6 at the JW Marriott Grande Lakes in Orlando.
HeartWare Receives FDA Approval To Enroll Supplemental Patient Cohort In Destination Therapy Trial
PR Newswire - Tue Aug 27, 8:10AM CDT
HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that the U.S. Food and Drug Administration (FDA) has approved an IDE (Investigational Device Exemption) Supplement that allows HeartWare to commence enrollment in an additional patient cohort for ENDURANCE, the Company's pivotal, Destination Therapy clinical study.
Investment Initiatives, Financial Results, Investor Conferences, Dividends, and FDA Approvals - Research Report on CareFusion, Teleflex, Cooper, HeartWare, and Thoratec
PR Newswire - Thu Aug 15, 7:00AM CDT
Editor Note: For more information about this release, please scroll to bottom.
HeartWare Presentation At The Canaccord Genuity 2013 Annual Growth Conference To Be Webcast
PR Newswire - Fri Aug 09, 3:00PM CDT
HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Canaccord Genuity 2013 Annual Growth Conference at 3:00 p.m. EDT on Wednesday, August 14, 2013. The conference is being held August 14-15 at the The InterContinental Boston.
HeartWare International Reports $50.8 Million In Second Quarter 2013 Revenue; 75% Increase From Second Quarter Of 2012
PR Newswire - Thu Aug 08, 6:00AM CDT
HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced revenue of $50.8 million for the second quarter ended June 30, 2013, a 75% increase compared to $29.1 million in revenue for the same period of 2012.
HeartWare Schedules Second Quarter Conference Call And Webcast
PR Newswire - Fri Jul 19, 5:00AM CDT
HeartWare International, Inc. (NASDAQ:HTWR, ASX:HIN) has scheduled a conference call to discuss its financial results for the three months ended June 30, 2013, at 8:00 a.m. U.S. Eastern Daylight Time on Thursday, August 8, 2013. The Company plans to release the financial results prior to the conference call.
Leadership Changes, New Studies, Acquisitions, New Care Facilities, and Business Transformations - Research Report on Cigna, HeartWare, Acadia, Magellan, and Haemonetics
PR Newswire - Tue Jun 25, 7:00AM CDT
Today, Wall Street Reports announced new research reports highlighting CIGNA Corporation (NYSE: CI), HeartWare International Inc. (NASDAQ: HTWR), Acadia Healthcare Company Inc. (NASDAQ: ACHC), Magellan Health Services Inc. (NASDAQ: MGLN), and Haemonetics Corporation (NYSE: HAE). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
HeartWare Receives Conditional Approval From FDA to Enroll Supplemental Patient Cohort in Destination Therapy Trial
PR Newswire - Mon Jun 17, 7:50AM CDT
HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that the U.S. Food and Drug Administration (FDA) has granted conditional approval to an IDE (Investigational Device Exemption) Supplement that allows HeartWare to commence enrollment in an additional patient cohort for ENDURANCE, the Company's pivotal, Destination Therapy clinical study.
HeartWare Presentation at the Wells Fargo Securities 2013 Healthcare Conference to be Webcast
PR Newswire - Thu Jun 13, 8:00AM CDT
HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Wells Fargo Securities Research and Economics 2013 Healthcare Conference at 9:25 a.m. EDT on Tuesday, June 18, 2013. The conference is being held June 18-19 at the The InterContinental Boston.
HeartWare International Announces Intention To Delist From Australian Securities Exchange (ASX)
PR Newswire - Wed Jun 12, 7:00AM CDT
HeartWare International, Inc. (NASDAQ:HTWR - ASX:HIN), today announced that it has requested and received approval from ASX Limited for its removal from the official list of ASX. Trading in HeartWare's CHESS Depositary Interests (CDIs) will be suspended on ASX at the close of market on September 10, 2013.
HeartWare Presentation At The Goldman Sachs 34th Annual Global Healthcare Conference To Be Webcast
PR Newswire - Tue Jun 04, 11:20AM CDT
HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Goldman Sachs 34th Annual Global Healthcare Conference at 8:00 a.m. PDT (11:00 am EDT) on Wednesday, June 12, 2013. The conference is being held June 11-13 at the Terranea Resort in Rancho Palos Verdes, CA.
HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be Webcast
PR Newswire - Thu May 16, 3:00PM CDT
HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the 2013 UBS Global Healthcare Conference at 11:00 a.m. EDT on Monday, May 20, 2013. The conference is being held May 20-22, 2013 at the Sheraton New York Hotel.
HeartWare Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference to be Webcast
PR Newswire - Fri May 10, 12:59PM CDT
HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Bank of America Merrill Lynch 2013 Health Care Conference at 8:00 a.m. PDT (11:00 am EDT) on Thursday, May 16, 2013. The conference is being held May 14-16, 2013 at the Encore at Wynn in Las Vegas.
HeartWare International Reports $49.2 Million In First Quarter 2013 Revenue; 87% Increase From First Quarter Of 2012
PR Newswire - Mon Apr 29, 3:10PM CDT
HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced revenue of $49.2 million for the first quarter ended March 31, 2013, an 87% increase compared to $26.4 million in revenue for the same period of 2012.
HeartWare Schedules First Quarter Conference Call And Webcast
PR Newswire - Mon Apr 15, 5:00AM CDT
HeartWare International, Inc. (NASDAQ: HTWR, ASX:HIN) has scheduled a conference call to discuss its financial results for the three months ended March 31, 2013, at 5:00 p.m. U.S. Eastern Daylight Time on Monday, April 29, 2013. The Company plans to release the financial results prior to the conference call.
HeartWare International, Inc. Announces Closing of Public Offering of Common Stock
PR Newswire - Mon Mar 18, 11:21AM CDT
HeartWare International, Inc. (Nasdaq: HTWR, ASX: HIN) ("HeartWare") announced today the completion of a public offering of 1,725,000 shares of common stock, at a price per share of $86.45 pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission ("SEC") on December 9, 2010. This amount includes 225,000 additional shares of common stock sold pursuant to the underwriters' exercise in full of their option to purchase additional shares of common stock to cover over-allotments.
HeartWare International, Inc. Announces Pricing of Public Offering of Common Stock
PR Newswire - Tue Mar 12, 7:41PM CDT
HeartWare International, Inc. (Nasdaq: HTWR, ASX: HIN) ("HeartWare") announced today the pricing of a public offering of 1,500,000 shares of common stock at a price per share of $86.45 pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission ("SEC"). HeartWare also granted the underwriters an option to purchase up to an additional 225,000 shares to cover over-allotments, if any.
HeartWare International, Inc. Announces Public Offering of Common Stock
PR Newswire - Mon Mar 11, 3:00PM CDT
HeartWare International, Inc. (Nasdaq: HTWR, ASX: HIN) ("HeartWare") announced today its intention to offer, subject to market and other conditions, 1,500,000 shares of common stock pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission ("SEC"). HeartWare also intends to grant the underwriters an option to purchase up to an additional 225,000 shares to cover over-allotments, if any.
Leveraging Results to Drive New Innovation - Research Report on Medtronic, Inc., Edwards Lifesciences, Cyberonics, Inc., HeartWare International and Luxottica Group SpA
PR Newswire - Thu Mar 07, 7:00AM CST
Today, Investors Alliance announced new research reports highlighting Medtronic, Inc. (NYSE:MDT), Edwards Lifesciences Corp (NYSE:EW), Cyberonics, Inc. (NASDAQ:CYBX), HeartWare International Inc (NASDAQ:HTWR) and Luxottica Group SpA (NYSE:LUX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
HeartWare Presentation at the Barclays Capital 2013 Global Healthcare Conference To Be Webcast
PR Newswire - Wed Mar 06, 8:00AM CST
HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Barclays Capital 2013 Global Healthcare Conference at 11:15 a.m. EDT on Tuesday, March 12, 2013. The conference is being held March 12-14, 2013 at the Loews Miami Hotel, Florida.
HeartWare Presentation At Raymond James 34th Annual Institutional Investors Conference To Be Webcast
PR Newswire - Thu Feb 28, 9:47AM CST
HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Raymond James 34th Annual Institutional Investors Conference at 1:05 p.m. Eastern Standard Time on Tuesday, March 5, 2013. The conference is being held March 3-6 at the JW Marriott Grande Lakes in Orlando.
